J B Chemicals & Pharmaceuticals Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

J B Chemicals & Pharmaceuticals has allotted 2,500 equity shares under ESOS on 06 December 2025. Consequently, the issued, subscribed and paid-up capital has increased from 15,66,48,456 equity shares of Re. 1 each to 15,66,50,956 equity shares of Re. 1 each.

Powered by Capital Market - Live News

J B Chemicals & Pharmaceuticals Ltd is down for a fifth straight session today. The stock is quoting at Rs 1731, down 1% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.29% on the day, quoting at 26115.75. The Sensex is at 85365.62, down 0.31%.J B Chemicals & Pharmaceuticals Ltd has added around 1.3% in last one month.Meanwhile, Nifty Pharma index of which J B Chemicals & Pharmaceuticals Ltd is a constituent, has increased around 0.76% in last one month and is currently quoting at 22687.55, down 0.15% on the day. The volume in the stock stood at 1.69 lakh shares today, compared to the daily average of 2.14 lakh shares in last one month.

The PE of the stock is 38.76 based on TTM earnings ending September 25.

Powered by Capital Market - Live News

Profit before tax (PBT) stood at Rs 279.15 crore in Q2 FY26, up 18% from Rs 236.53 crore reported in the corresponding quarter last year.

In Q2 FY26, operating EBITDA stood at Rs 319 crore, up 12%, compared with Rs 285 crore posted in the same quarter last year. Operating EBITDA margin stood at 29.4% in Q2 FY26 as against 28.4% in Q2 FY25.

Nikhil Chopra, CEO and whole-time director of JB Pharma, stated, ?The company?s domestic business continued to outperform the market, with all major brands delivering robust growth. Our focus on driving steady volume growth across key brands?including recently acquired portfolios?continues to yield good results. On the international front, momentum in our CDMO business has returned, supported by a solid order book that positions us for further growth in the second half of the year.

Over the years, JB has consistently delivered strong revenue and margin performance. We are confident in sustaining this positive momentum as we progress toward our operational and strategic goals for the current year and beyond. As we chart the path ahead, our focus remains on building a progressive, agile, and future-ready organization.?

JB Chemicals & Pharmaceuticals manufactures a wide range of pharmaceutical formulation specialties, radiodiagnostics, APIs, and intermediates.

Shares of JB Chemicals & Pharmaceuticals shed 0.41% to Rs 1,819.25 on the BSE.

Powered by Capital Market - Live News

Net profit of J B Chemicals & Pharmaceuticals rose 19.05% to Rs 207.82 crore in the quarter ended September 2025 as against Rs 174.57 crore during the previous quarter ended September 2024. Sales rose 8.42% to Rs 1084.90 crore in the quarter ended September 2025 as against Rs 1000.62 crore during the previous quarter ended September 2024.

Powered by Capital Market - Live News